Compare JELD & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JELD | MDWD |
|---|---|---|
| Founded | 1960 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Forest Products | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 181.1M |
| IPO Year | 2016 | 2013 |
| Metric | JELD | MDWD |
|---|---|---|
| Price | $1.80 | $14.12 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 1 |
| Target Price | $3.43 | ★ $36.00 |
| AVG Volume (30 Days) | ★ 1.4M | 105.9K |
| Earning Date | 05-04-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,211,181,000.00 | N/A |
| Revenue This Year | N/A | $48.92 |
| Revenue Next Year | $2.06 | $35.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.93 | $13.54 |
| 52 Week High | $6.98 | $21.26 |
| Indicator | JELD | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 41.31 |
| Support Level | $1.64 | $13.54 |
| Resistance Level | $2.15 | $18.49 |
| Average True Range (ATR) | 0.19 | 0.55 |
| MACD | -0.03 | 0.07 |
| Stochastic Oscillator | 36.36 | 48.28 |
JELD-WEN Holding Inc is engaged in door and window manufacturing. The company designs, produces, and distributes interior and exterior building products, offering a selection of doors, windows, walls, and related products. The products are used in the new construction of residential and non-residential buildings. The firm's operating segments are North America, and Europe. It generates a majority of its revenue from North America.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.